CA-VERIMATRIX/TELESTREAM
29.8.2022 17:46:43 CEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, and Telestream, a global leader in video quality monitoring, test and measurement solutions, today announced that Surveyor ABR Active, Telestream iQ's ABR streaming QoE and QoS monitoring technology, is integrated within Verimatrix StreamkeeperSM Multi-DRM, available in the Verimatrix Secure Delivery Platform.
Through the integration, Telestream further builds on its innovative offerings for the digital video industry which include workflow automation, media processing, and quality monitoring solutions for the production and distribution of video. Telestream’s integration with Streamkeeper Multi-DRM allows users to capitalize on Verimatrix’ s cost-effective cloud-based solution while maintaining full visibility into video and audio content quality. Together, Verimatrix and Telestream accelerate time to market while maintaining service visibility for operators.
Verimatrix Streamkeeper Multi-DRM delivers studio endorsed best practices for content protection, with meticulous focus on ensuring superior video viewer experiences. As a suite of adaptive cybersecurity technologies that include and go beyond DRM, Streamkeeper allows video service providers to manage revenue risk in a world of continuously changing threats from video piracy and cybercriminals.
Telestream’s video quality monitoring solutions are trusted worldwide to provide video service assurance and operational visibility for valuable live and on-demand video services. As digital workflows move to the cloud, Telestream’s pedigree monitoring solutions, coupled with Verimatrix, means those planning to migrate their video workflows to the cloud will have equal or better operational visibility than ever before.
Telestream iQ provides full video and audio quality analysis both at the transcoding location and post CDN for live and on-demand services, allowing operators full visibility into content quality issues – even with full security encryption in place. Telestream iQ’s solutions ensure that audio and video quality errors such as compression errors, pixelization, black screen, still frame, and audio loudness are caught early, allowing rapid time-to-resolution and the ongoing protection of revenue and reputation.
“A longstanding alliance partner of Verimatrix, Telestream is proud to be one of its first partners to integrate with Streamkeeper Multi-DRM,” said Joel Daly, vice president of product management at Telestream. “Together we provide a solution that builds security, service assurance and operational visibility into cloud video workflows, de-risking the migration to cloud for global content and video service providers.”
“We’re extremely pleased to work with such highly-recognized industry visionaries such as Telestream as we continue to widen the number the number of integrated solutions available within Verimatrix Streamkeeper Multi-DRM,” said Sebastian Braun, senior director of product management at Verimatrix. “We’re pleased to continue our acceleration of additive value adoption through a global network of trusted partners.”
Verimatrix Streamkeeper is available in multiple tiers and includes features such as a real-time performance dashboard, on-call support integrations and alerts, individual device risk scoring and anti-piracy countermeasures.
Surveyor ABR Active provides essential insights that enable content owners and streaming service providers to manage critical issues relate to Quality of Service (QoS) and Quality of Experience (QoE) for live and on-demand services. It acts as the most critical viewer, measuring video flows for every bitrate variant and format.
For more information about Verimatrix Streamkeeper, visit: www.verimatrix.com/products/streamkeeper.
About Telestream
For nearly 25 years, Telestream® has been at the forefront of innovation in the digital video industry. The company develops products for media processing and workflow orchestration, live capture, streaming, production, video quality assurance, virtual events and video hosting, content management, and video and audio test solutions. Available on premises or in the cloud as well as in hybrid combinations, Telestream solutions make it possible to reliably get video content to any audience, regardless of how it is created, distributed or viewed. Telestream is privately held with corporate headquarters located in Nevada City, California and Westwood, Massachusetts.
For company and product information, visit www.Telestream.net.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005371/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom